Kailera Therapeutics Inc. (KLRA)
KLRA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | KLRA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2026 |
| SEC CIK | 0002096997 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
New registrant: no annual report filed under this company yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $106.5M cash; operating cash flow -$77.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 129,850,481 (2026-10-29). | Cover page 2026-10-29 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-04-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $167.4M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$95.7M | -$133.7M | $106.5M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q3 2026 2026-06-30 | Not filed | -$111.3M | -$77.5M | $130.3M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q3 2026 2026-03-31 | Not filed | -$78.9M | -$68.3M | $111.8M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q3 2026 2025-09-30 | Not filed | -$39.6M | -$29.7M | $97.9M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q3 2026 2025-06-30 | Not filed | -$28.9M | -$26.2M | $101.4M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q3 2026 2025-03-31 | Not filed | -$18.0M | -$18.2M | $101.8M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2026-04-17 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
Source: SEC EDGAR submissions feed, 64 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.3% |
| 1 month | +23.2% |
| 3 months | -26.2% |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -49.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SRPT | Sarepta Therapeutics Inc. Common Stock (DE) | $15.13 | -5.85% | $1.6B |
| RARE | Ultragenyx Pharmaceutical Inc. | $15.90 | -1.12% | $1.6B |
| ANIP | ANI Pharmaceuticals Inc. | $70.89 | -0.77% | $1.6B |
| NRIX | Nurix Therapeutics Inc. | $14.73 | -4.84% | $1.6B |
| ADRX | ADARx Pharmaceuticals Inc. | $14.00 | -1.41% | $1.6B |
| PGEN | Precigen Inc. | $4.30 | -5.29% | $1.5B |
| QURE | uniQure N.V. | $21.88 | -8.11% | $1.5B |
| STOK | Stoke Therapeutics Inc. | $26.63 | -0.19% | $1.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier